Global anti osteoporosis therapy and fracture healing market is estimated to grow at a CAGR of 3.0% during the forecast period. A study was conducted to calculate the number of patients with hip fractures who subsequently initiate treatment with anti-osteoporotic medicine. Copenhagen University Hospital, Herlev, conducted a study from June 2019 to May 2020. A total of 627 patients were admitted with a hip or near-hip fracture in the one-year study period. At the time of the hip fracture, 570 patients were 65 years of age or older, and 74% were women. Men were slightly younger than women at the time of fracture. At follow-up, 26% of the patients had died. However, the study unveiled that men had a higher death rate than women. Additionally, various initiatives programs, and spending on R&D by regulatory bodies, strengthen the market growth. For instance, in June 2021, a new joint initiative by the International Osteoporosis Foundation and Asia Pacific Orthopaedic Association calls on orthopaedic surgeons to strengthen collaboration with physicians to improve secondary fracture prevention and patient outcomes. The new publication features key messages related to fracture management, post-fracture rehabilitation, fracture healing and national fracture registries. Asian countries are facing the most marked increase in fragility fractures globally, with the number of people at high fracture risk expected to double from 2010-2030.
Browse the full report description of “Anti Osteoporosis Therapy and Fracture Healing Market Size, Share & Trends Analysis Report by Drug Type (Calcitonin, Bisphosphonates, Hormone Replacement Therapy, Anabolics, and Others), by Route of Administration (Oral and Injectable), and by Distribution Channel (Clinics, Hospital Pharmacies, Drug Stores, Retail Pharmacies, and E-Commerce) Forecast Period (2023-2030)” at https://www.omrglobal.com/industry-reports/anti-osteoporosis-therapy-and-fracture-healing-market
Moreover, according to the International osteoporosis foundation, in 2022, there are 6.2 million Australians over the age of 50 with osteoporosis or osteopenia. That is a 31% increase from 2012. as per the same source, Asian countries will face the most marked increase in fractures globally, with projections suggesting that by 2050, 50% of hip fractures will occur in Asia, the majority of which will happen in China. The number of individuals at high fracture risk in the region is expected to double from 2010- 2030.
Market Coverage
• The market number available for – 2022-2030
• Base year- 2022
• Forecast period- 2023-2030
• Segment Covered-
o By Drug Type
o By Route of Administration
o By Application
• Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
• Competitive Landscape- including GlaxoSmithKline, Medtronic Plc, Merck & Co. Inc.,Pfizer, and others.
Key questions addressed by the report
• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?
Global Anti Osteoporosis Therapy and Fracture Healing Market Report Segment
By Drug Type
• Calcitonin
• Bisphosphonates
o Alendronate (Fosamax)
o Risedronate (Actonel)
o Ibandronate (Boniva)
o Zoledronic acid (Reclast)
By Route of Administration
By Distribution Channel
Global Anti Osteoporosis Therapy and Fracture Healing Market Report Segment by Region
North America
• United States
• Canada
Europe
• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe
Asia-Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
Rest of the World
• Latin America
• Middle East & Africa
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/anti-osteoporosis-therapy-and-fracture-healing-market